Alterity Therapeutics to Present at ASX SMIDcaps Conference
Released
Released
Announcement PDF
Alterity Therapeutics to Present at the ASX SMIDcaps Conference
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 18 September 2026: Alterity
Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology
company dedicated to developing disease modifying treatments for neurodegenerative diseases,
today announced that Lawrence Gozlan, Non-Executive Director, will present at the ASX
SMIDcaps Conference on Wednesday, September 23, 2026 at 1:55 p.m. AEST.
A link to the event registration and archived webcast may be accessed on Alterity Therapeutics
website under the Investors section: Events and Presentations.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate
future for people living with neurodegenerative diseases. The Company is focused on developing
disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian
disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly
progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful
efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants
with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in
participants with advanced MSA. In addition, Alterity has a broad drug discovery platform
generating patentable chemical compounds to treat the underlying pathology of neurological
diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For
further information please visit the Company’s website at https://alteritytx.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Contacts:
Investors
Elyse Shapiro
ir@alteritytx.com
Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386
Media
Melissa Tempra
NWR Communications
melissa@nwrcommunications.com.au
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520
Share your feedback
Discover